Shardul Amarchand Mangaldas & Co has advised Krishna Institute of Medical Sciences Limited (KIMS) on its ₹1,500 crore Qualified Institutions Placement (QIP) — one of the more significant healthcare capital markets transactions of 2026. The KIMS QIP Shardul Amarchand Mangaldas mandate drew participation from a wide cross-section of institutional investors, including a multilateral development finance institution. The QIP closed on June 19, 2026, with proceeds earmarked for debt reduction across KIMS and its subsidiaries.
Introduction
Krishna Institute of Medical Sciences Limited (KIMS), one of India’s key healthcare corporate groups, has successfully raised ₹1,500 crore through a Qualified Institutions Placement of equity shares. The QIP involved the issuance of new shares to Qualified Institutional Buyers (QIBs) in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Shardul Amarchand Mangaldas & Co acted as legal counsel to KIMS on the transaction.
The placement attracted a diverse set of institutional investors. These included the International Finance Corporation (IFC), alongside leading domestic mutual funds and insurance companies — specifically HSBC Mutual Fund, Edelweiss Mutual Fund, Axis Mutual Fund, ICICI Prudential Life Insurance, HDFC Life Insurance, and Kotak Mahindra Life Insurance. The QIP closed on June 19, 2026, with 1,98,67,549 equity shares allotted at ₹755 per share.
The proceeds are proposed to be utilised towards repayment and/or prepayment of certain outstanding borrowings availed by KIMS and certain of its subsidiaries. Further details on the allocation timeline were not disclosed.
Deal Value
₹1,500 crore (approximately USD 158 million)
Shares were allotted at ₹755 per share, representing a slight discount to the prevailing market price at the time of issuance — a standard practice in QIP structures to attract institutional participation. The quantum was the full amount approved by the KIMS Board of Directors and Finance Committee.
Legal Teams Involved
Shardul Amarchand Mangaldas & Co acted as sole legal counsel to the issuer, Krishna Institute of Medical Sciences Limited (KIMS).
The transaction team comprised:
- Prashant Gupta — Partner and National Practice Head – Capital Markets
- Ruth Chenchiah — Partner
- Ritika Khare — Principal Associate
- Anoushka PV — Senior Associate
- Anaya Jain — Associate
- Kunika Agarwal — Associate
Further details regarding legal counsel to the placement agents or institutional investors were not disclosed.
Significance and Impact
The transaction is significant for several reasons. First, the participation of the International Finance Corporation (IFC) — the private sector financing arm of the World Bank Group — alongside domestic institutions signals strong institutional confidence in KIMS’s growth trajectory and governance standards. IFC’s involvement typically carries an imprimatur that can attract other long-only institutional investors.
Second, the use of proceeds is squarely directed at balance sheet repair. By channelling the ₹1,500 crore towards repayment and prepayment of outstanding borrowings across KIMS and its subsidiaries, the company strengthens its financial position ahead of a planned capacity expansion. This debt-reduction focus is a meaningful signal to the market about management’s capital discipline.
Third, the breadth of the investor base — spanning mutual funds, life insurers, and a multilateral lender — reflects the depth of India’s institutional investor pool for healthcare equity issuances. The QIP route, which permits no regulatory lock-in and does not require upfront disclosure of investor names pre-allotment, made it an efficient fundraising mechanism for a transaction of this scale.
Track the latest Indian law firm deal activity on our Deal Meter.
The ₹1,500 crore KIMS QIP, advised by Shardul Amarchand Mangaldas & Co, is a concluded transaction that underscores the continued appetite of institutional investors — domestic and multilateral — for quality healthcare equity issuances in India. With proceeds directed towards debt reduction, KIMS enters its next phase of expansion from a strengthened balance sheet position. The deal closed on June 19, 2026, with formal allotment of shares on the NSE and BSE to follow.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
